
Nurturing Wellbeing in Our Workspace: Prioritizing People’s Growth
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vibrant team. Today, let’s delve into how our Workplace Wellbeing initiatives align with our ESG principles, fostering a culture of growth and balance. These are more than just initiatives, but are our way to care about Scailyters:
Investing in people’s Growth: Our training and development programs aren’t just about skill enhancement. They represent our investment in our employees’ growth. From internal trainings that cater to domain expertise, to external courses that broaden horizons, we’re dedicated to empowering our team members.
Flexibility & Connection: Our work mode policy underscores our belief in flexibility. Whether people prefer the office environment or the comfort of home, we trust our Scailyters to make the choice that enhances personal productivity and overall wellbeing, as well as team productivity. And when we gather for team events or our annual retreat, it’s about more than just work – it’s about building connections and sparking creativity.
Healthy Habits, Happy Minds: Through our lunch subsidy program, we’re not just encouraging healthy eating, but also providing moments for our employees to unwind and connect over meals. After all, a healthy body nurtures a happy mind.
Recognition & Celebration: Achievements deserve recognition, and at Scailyte, we celebrate them! Our peer bonus and gift programs are designed to appreciate exceptional efforts and milestones. Because in a thriving ecosystem, every contribution matters.
The heart of our ESG mission lies in nurturing a workplace where growth is inherent, balance is celebrated, and every Scailyter thrives. Stay tuned as we continue this journey, evolving and innovating for our team members’ wellbeing.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...